The epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy. 1
|
|
- Dayna Dalton
- 5 years ago
- Views:
Transcription
1 Association of Diffuse, Random Pulmonary Metastases, Including Miliary Metastases, With Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma Yosuke Togashi, MD 1 ; Katsuhiro Masago, MD, PhD 1 ; Takeshi Kubo, MD 2 ; Yuichi Sakamori, MD 1 ; Young Hak Kim, MD 1 ; Yukimasa Hatachi, MD 1 ; Akiko Fukuhara, MD 1 ; Tadashi Mio, MD, PhD 1 ; Kaori Togashi, MD, PhD 2 ; and Michiaki Mishima, MD, PhD 1 BACKGROUND: Although the association of multiple pulmonary metastases, and particularly miliary metastases, with response to gefitinib treatment in patients with nonsmall cell lung cancer has been reported, the association of miliary pulmonary metastases with epidermal growth factor receptor gene () mutations remains unclear. METH- ODS: The authors retrospectively investigated the association of diffuse, random pulmonary metastases in patients with lung adenocarcinoma. The study included 163 Japanese patients who had unresectable, advanced lung adenocarcinoma diagnosed between April 2003 and March Computed tomography scans that were obtained at the time of diagnosis were analyzed by 2 investigators. For the purposes of this study, diffuse, random pulmonary metastases were defined as multiple nodules (n ¼ 50; 3 cm in greatest dimension) distributed diffusely and randomly throughout the lungs. RESULTS: Of 163 patients, 55 had pulmonary metastases, and mutations were detected in 22 of those 55 patients. The mutations were identified preferentially among women (P ¼.15) and were identified significantly among patients who had a smoking history of <10 pack-years (P ¼.0057). Diffuse, random pulmonary metastases were identified in 11 of 22 patients who had mutations and in 4 of 33 patients who had the wildtype (P ¼.0043). On the basis of multivariate analyses, mutations were associated independently with a smoking history of <10 pack-years (P ¼.026) and with diffuse, random pulmonary metastases (P ¼.012). CONCLU- SIONS: When patients with lung adenocarcinomas who had mutations developed pulmonary metastases, they tended to be diffuse and random, including military metastases. However, such metastases were much less common in patients who had lung adenocarcinomas with wild-type. Cancer 2011;117: VC 2010 American Cancer Society. KEYWORDS: pulmonary metastases, miliary metastases, epidermal growth factor receptor gene mutation, tyrosine kinase inhibitor, lung cancer. The epidermal growth factor receptor () is recognized as an important molecular target in cancer therapy. 1 Because patients with nonsmall cell lung cancer (NSCLC) who have somatic activating mutations of the gene generally respond to tyrosine kinase inhibitors (TKIs) (gefitinib or erlotinib), such mutations are very important markers and are useful in deciding the course of treatment for patients with NSCLC. 2-4 Although miliary pulmonary metastases are observed most often in patients with thyroid carcinoma, 5 these metastases sometimes are observed in patients with lung cancer; an association between multiple pulmonary metastases, particularly miliary metastases, and response to gefitinib therapy in patients with NSCLC has been reported. 6 Moreover, we recently reported that 1 patient with thyroid carcinoma who had an mutation 7 had miliary pulmonary metastases and responded to gefitinib therapy. From this finding, we hypothesized that, for cancers in which the patient has accompanying mutation(s), including NSCLC and thyroid carcinoma, miliary pulmonary metastases often develop. In this Corresponding author: Katsuhiro Masago, MD, PhD, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-Ku, Kyoto Japan; Fax: (011) ; masago@kuhp.kyoto-u.ac.jp. 1 Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 2 Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan DOI: /cncr.25618, Received: March 31, 2010; Revised: June 27, 2010; Accepted: August 3, 2010, Published online September 30, 2010 in Wiley Online Library (wileyonlinelibrary.com) Cancer February 15,
2 Table 1. Patient Characteristics (n¼55) Characteristic No. of Patients (%) Median/mean age [range], y 68/67.7 [35-86] Sex Women 31 (56.4) Men 24 (43.6) Smoking status Nonsmoker 25 (45.5) Smoker 30 (54.5) Former 23 (41.8) Current 7 (12.7) Performance status a (85.5) (14.5) Administration of -TKIs Yes 31 (56.4) No 24 (43.6) First or second-line therapy with -TKIs Yes 24 (43.6) No 31 (56.4) Mutated 22 (40) Wild type 33 (60) indicates epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors. a Performance status was evaluated before the administration of - TKIs. article, we retrospectively investigated the association of diffuse, random pulmonary metastases, including miliary metastases, with mutations in patients with lung adenocarcinoma. MATERIALS AND METHODS Patients Japanese patients (n ¼ 163) with unresectable, advanced lung adenocarcinoma who were diagnosed between April 2003 and March 2010 and who had their tumors analyzed for gene mutation at Kyoto University Hospital were enrolled in this study. Patient characteristics are listed in Table 1. We obtained written informed consent from all patients. Mutational Analysis Formalin-fixed, paraffin-embedded tissue blocks or cytologic samples were used for DNA analysis. We adopted the peptic nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp method, according to previously described protocols. 8 Briefly, PNA Figure 1. These chest computed tomography images from a human aged 35 years who was a current smoker with an epithelial growth factor receptor gene mutation (L858R) reveal miliary pulmonary metastases. (A) Profuse, tiny, discrete, rounded, pulmonary opacities that generally are uniform in size are distributed diffusely throughout the lungs. A primary lesion was identified in the right upper lobe (arrow). (B) Four weeks after the initiation of gefitinib, the patient achieved a partial response. clamp primers inhibit amplification of the wild-type sequence, and LNA probes are used to detect specific mutant sequences in the presence of wild-type sequences. A synergistic effect of these primers causes specific PCR amplification of mutant sequences. Specific PNA-LNA probe sets for each mutation were developed to detect >95% of the mutations reported previously in Japan Cancer February 15, 2011
3 Radiologic Findings in Lung Cancer/Togashi et al Figure 2. These chest computed tomography images from a women aged 67 years who was a nonsmoker with an epithelial growth factor receptor gene mutation (L858R) reveal diffuse, random pulmonary (nonmiliary) metastases. (A) Multiple nodules are distributed diffusely throughout the lungs and a primary lesion in the right upper lobe (arrow). The nodules are not uniform in size. (B) Four weeks after the initiation of erlotinib, the patient achieved a partial response. Figure 3. These chest computed tomography images from a women aged 79 years who was an exsmoker with the wildtype epithelial growth factor receptor gene reveal miliary pulmonary metastases. (A) Bilateral pleural effusions and profuse, tiny, discrete, rounded pulmonary opacities that generally are uniform in size are distributed diffusely throughout the lungs. (B) Four weeks after the initiation of gefitinib, the patient achieved a partial response. Imaging Studies Two physicians who were blinded to results from the mutational analyses reviewed the chest computed tomography (CT) scans, including high-resolution CT scans, that were obtained at the time of lung cancer diagnosis. For the purposes of this study, diffuse, random pulmonary metastases, including miliary metastases, were defined as multiple nodules (a count 50 nodules and 3 cm in greatest dimension) that were distributed diffusely and randomly throughout the lungs. We used a previous definition of miliary pulmonary metastases, 10 that is, profuse, tiny, discrete, rounded pulmonary opacities (3 mm in greatest dimension) generally uniform in size that are distributed diffusely and randomly throughout the lungs (Figs. 1-3). To avoid confusion, we distinguished a bronchioloalveolar carcinoma (BAC) pattern, which appears as centrolobular distribution (Fig. 4). Cancer February 15,
4 Statistical Analysis The univariate correlation between each independent variable was examined using either the chi-square test or the Fisher exact test. A multivariate logistic regression model was applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Only those variables with P values <.1 in univariate analysis were included in the multivariate analysis. All tests were 2-tailed, and P values <.05 were considered statistically significant. All preceding statistical analyses were performed using JMP 8 software (SAS Institute, Cary, NC). Figure 4. These chest computed tomography images from a women aged 36 years who was an exsmoker with the wildtype epithelial growth factor receptor gene reveal a bronchioloalveolar carcinoma pattern. (A) Patchy consolidation, ground-glass opacity, and centrolobular nodules are distributed bilaterally in the lower lungs. (B) Four weeks after the initiation of gefitinib, she developed progressive disease. RESULTS mutations were detected in 77 of 163 patients (47%) and were not detected in 86 of 163 patients (53%). Twenty-two of 77 patients who had mutations had lung metastases (29%), and 33 of 86 patients with wildtype had pulmonary metastases (38%; P ¼.19; chi-square test). The clinical characteristics of the 55 patients who had pulmonary metastases are summarized in Table 1. The profiles of patients with mutations were similar to those reported previously. 11,12 The mutations were identified preferentially (but not significantly) among women (15 of 31 patients; P ¼.15; chisquare test) but were identified significantly in patients who had a smoking history of <10 pack-years (17 of 30 patients; P ¼.0057; chi-square test). Diffuse, random pulmonary metastases and miliary metastases were identified in 11 patients (50%) and 7 patients (32%), respectively, of the 22 patients who had mutations and in 4 patients (12%) and 1 patient (3%), respectively, of the 33 patients who had wild-type. mutations were associated significantly with both diffuse, random pulmonary metastases and miliary metastases (P ¼.0043 and P ¼.0049, respectively; Fisher exact test) (Table 2). In contrast, mutations were not associated with a BAC pattern (P ¼.72; Fisher exact test). -TKIs were administered to 31 of 55 patients who had pulmonary metastases, and 19 of those 31 patients (61%) achieved a partial response (Table 3). -TKIs were more administered frequently to patients who had mutations (18 of 22 patients; 82%) than to patients who had the wild-type gene (13 of 33 patients; 39%; P ¼.0024; Fisher exact test). The response rate to -TKIs was higher preferentially (but not significantly) among women (15 of 22 patients; P ¼.25; Fisher exact test) and among patients who had a smoking history of <10 pack-years (15 of 21 patients; P ¼.13; Fisher exact test). In contrast, the response rate was significantly higher among patients who had mutations (16 of 18 patients; 89%) than among patients who had the wild-type gene (3 of 13 patients; 23%; P ¼.0005; Fisher exact test). In addition, the response rate was significantly higher in patients who had diffuse, random pulmonary metastases (11 of 13 patients; 85%) than in patients who had other pulmonary metastases (8 of 18 patients; 44%; P ¼.032; Fisher exact 822 Cancer February 15, 2011
5 Radiologic Findings in Lung Cancer/Togashi et al Table 2. Clinical Characteristics of Patients With Pulmonary Metastases (n¼55) Characteristic No. of Patients P Mutated Wild-Type No./total no. of patients 22/77 33/86.19 Age, y < Sex Men 7 17 Women Smoking status, pack-years < a Performance status Pulmonary metastasis pattern Diffuse random (miliary) 11 (7) 4 (1) Others (BAC) 11 (3) 29 (7).0043 a /.0049 a indicates epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; BAC, bronchioloalveolar pattern. a Statistically significant in Chi square test or Fisher exact test (P <.05). test). Four of the 15 patients who had diffuse, random pulmonary metastases had the wild-type gene. It is noteworthy that 2 of those 4 patients achieved a partial response to gefitinib (Fig. 3). We constructed a multivariate logistic regression model to identify the factors associated significantly with mutations and the response rate in this cohort. mutations were associated independently with a smoking history of <10 pack-years (OR, 4.40; 95%CI, ; P ¼.026) and with diffuse, random pulmonary metastases (OR, 6.12; 95%CI, ; P ¼.012) (Table 4). In contrast, the response rate was associated independently only with mutations (OR, 44.38; 95%CI, ; P ¼.0075) (Table 5). Miliary metastases were not analyzed, because the number of patients with such metastases was too small, and these were included in the diffuse, random pulmonary metastases category. Table 3. Clinical Characteristics of Patients With Pulmonary Metastases Who Received Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment (n¼31) Characteristic -TKI Response DISCUSSION Although this was a small, retrospective study, 11 of the 15 patients who had diffuse, random pulmonary metastases had mutations (73%), and mutations were associated independently with diffuse, random pulmonary metastases. That is, patients who had lung adenocarcinoma with mutations tended to develop diffuse, random pulmonary metastases, including miliary metastases. However, diffuse, random pulmonary metastases were much less common in lung adenocarcinomas with wild-type. The reason for this association is unclear. A random pulmonary metastatic pattern means that hematogenous metastasis is associated with angiogenesis. 13,14 It is long established that and its ligands play important roles in tumorigenesis. 15 However, signaling also may play an important role in cancer progression. Because signaling regulates the synthesis and secretion of several different angiogenic growth factors in tumor cells (ie, vascular endothelial growth factor, interleukin-8, and PR SD or PD No. of Patients Age, y < Sex Men 4 5 Women Smoking status, pack-years < Performance status No. of previous chemotherapy regimens a Pulmonary metastasis pattern Diffuse random (miliary) 11 (6) 2 (0) Others (BAC) 8 (1) 10 (3).032/.059 a Mutated Wild type a indicates epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PR, partial response; SD, stable disease; PD, progressive disease; BAC, bronchioloalveolar pattern. a Statistically significant in Chi square test or Fisher exact test (P <.05). P Cancer February 15,
6 Table 4. Association Between Patient Characteristics and Epidermal Growth Factor Receptor Mutations Variable OR (95% CI) P Univariate analysis Age (<70 y/ 70 y) 1.06 ( ).91 Sex (women/men) 2.28 ( ).15 Smoking history (<10 pack-years/ 10 pack-years) 5.23 ( ).0077 a Performance status (0 or 1/2) 1.13 ( ).88 Diffuse random pulmonary metastases (yes/no) 7.25 ( ).0037 a BAC pattern pulmonary metastases (no/yes) 1.69 ( ).48 Multivariate analysis Smoking history (<10 pack-years/ 10 pack-years) 4.40 ( ).026 a Diffuse random pulmonary metastases (yes/no) 6.12 ( ).012 a OR indicates odds ratio; CI, confidence interval; BAC, bronchioloalveolar pattern. a Statistically significant in logistic regression model analysis (P <.05). Table 5. Association Between Patient Characteristics and Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment Variable OR (95% CI) P Univariate analysis Age ( 70 y/<70 y) 3.33 ( ).14 Sex (women/men) 2.68 ( ).23 Smoking history (<10 pack-years/ 10 pack-years) 3.75 ( ).10 Performance status ( 2/0 or 1) 1.30 ( ).84 No. of previous chemotherapy regimens (0 or 1/ 2) ( ) 014 a Diffuse random pulmonary metastases (yes/no) 6.88 ( ).033 a BAC pattern pulmonary metastases (no/yes) 5.88 ( ).14 (mutated/wild type) ( ).0010 a Multivariate analysis No. of previous chemotherapy regimens (0 or 1/ 2) ( ).087 Diffuse random pulmonary metastases (yes/no) 9.61 ( ).12 (mutated/wild type) ( ).0075 a OR indicates odds ratio; CI, confidence interval; BAC, bronchioloalveolar pattern;, epidermal growth factor receptor. a Statistically significant in logistic regression model analysis (P <.05). basic fibroblast growth factor), mutations that accompany cancer, including NSCLC and thyroid carcinoma, tend to develop angiogenic metastases, such as diffuse, random pulmonary metastases. 16 On the basis of our multivariate analysis, the response rate to -TKIs was associated independently with mutations but not with diffuse, random pulmonary metastases. This finding may have been because most patients with diffuse, random pulmonary metastases also had mutations and had achieved a partial response to the -TKIs. That is, diffuse, random pulmonary metastases were associated strongly with mutations. It is noteworthy that 2 of the 4 patients who had diffuse, random pulmonary metastases and the wild-type achieved a partial response to gefitinib therapy. The PNA-LNA PCR clamp method that we adopted can detect >95% of the mutations reported previously in Japan, 9 and its sensitivity is 97%. 17 However, this method does not allow the detection of all mutations. We speculate that the 2 patients with the wild-type who achieved a partial response to gefitinib in fact had an mutation. -TKIs should be used in patients with diffuse, random pulmonary metastases even when the wild-type is present, because there is a possibility that such patients in fact have an mutation. Although, according to some previous reports, BAC pathologic subtype was a predictor of response to gefitinib, and mutations were observed preferentially in tumors that had BAC features, others reported that there was no association between BAC subtype and mutations. 21,22 In our study population, there was no association between a BAC pattern and mutations or response to gefitinib. However, a BAC pattern based 824 Cancer February 15, 2011
7 Radiologic Findings in Lung Cancer/Togashi et al on imaging appearance may include pathologic BAC histology. Although this was a small, retrospective study, we observed an association between mutations and diffuse, random pulmonary metastases, including miliary metastases. The method that we used to detect mutations cannot detect all mutations. Therefore, to avoid missing mutations, larger studies to identify the features of mutations associated with cancer should be performed. We speculate that NSCLC-associated mutations have behavior similar to that of thyroid carcinoma-associated mutations, such as the development of diffuse, random pulmonary metastases, including miliary metastases. In the future, it may be possible to establish a new category for mutation-associated cancers that would include NSCLC and thyroid carcinoma. CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. REFERENCES 1. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23: Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in nonsmall cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12: Riely GJ, Pao W, Pham D, et al. Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12: Yamamoto H, Toyooka S, Mitsudomi T. Impact of mutation analysis in nonsmall cell lung cancer. Lung Cancer. 2009;63: Herold CJ, Bankier AA, Fleischmann D. Lung metastases. Eur Radiol. 1996;6: Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced nonsmall-cell lung cancer. Curr Med Res Opin. 2006;22: Masago K, Asato R, Fujita S, et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer. 2009;124: Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in nonsmall cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65: Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64: Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246: Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98: Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007;13: Lee KS, Kim TS, Han J, et al. Diffuse micronodular lung disease: HRCT and pathologic findings. J Comput Assist Tomogr. 1999;23: Xu Y, Liu YJ, Yu Q. Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. Cancer Res. 2004;64: Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: gene and cancer. FEBS J. 2010;277: De Luca A, Carotenuto A, Rachiglio A, et al. The role of the signaling in tumor microenvironment. J Cell Physiol. 2008;214: Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for nonsmall cell lung cancers. Cancer Sci. 2007;98: Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol. 2004;22: Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350: Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101: Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97: Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, mutations and gene expression analysis. Am J Surg Pathol. 2008;32: Cancer February 15,
ANTICANCER RESEARCH 26: (2006)
Diffuse Micronodular Pulmonary Metastasis of Lung Adenocarcinoma Predicts Gefitinib Response in Association with Epidermal Growth Factor Receptor Mutations MAKOTO KOBAYASHI 1, TAMOTSU TAKEUCHI 2, KENTARO
More informationONCOLOGY LETTERS 8: , 2014
ONCOLOGY LETTERS 8: 813-818, 2014 Investigation of the epidermal growth factor receptor mutation rate in non small cell lung cancer patients and the analysis of associated risk factors using logistic regression
More informationLung cancer is the most common cause of cancer death in
ORIGINAL ARTICLE Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? Catherine
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationoncology reports 26: , 2011
oncology reports 26: 795-803, 2011 Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationThere has been a growing interest in lung cancer in neversmokers,
ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationClinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
Pulmonary Medicine Volume 2011, Article ID 290132, 5 pages doi:10.1155/2011/290132 Clinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the
More informationRepeated Favorable Responses to Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
http://dx.doi.org/10.4046/trd.2013.74.3.129 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:129-133 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationKey Words. Lung cancer EGFR Mutation Genetic screening
The Oncologist Lung Cancer Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing LECIA V. SEQUIST, VICTORIA A. JOSHI, PASI A. JÄNNE, ALONA
More informationThe epidermal growth factor receptor (EGFR) is recognized
ORIGINAL ARTICLE Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer Yosuke Togashi, MD,* Katsuhiro
More informationLung cancer is the leading cause of cancer death worldwide.
ORIGINAL ARTICLE Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationRecent advances in high-resolution computed tomography
ORIGINAL ARTICLE Epidermal Growth Factor Receptor Mutations in Multicentric Lung Adenocarcinomas and Atypical Adenomatous Hyperplasias Koei Ikeda, MD, PhD,* Hiroaki Nomori, MD, PhD,* Yasuomi Ohba, MD,*
More informationLung cancer is the leading cause of cancer death throughout
ORIGINAL ARTICLE Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs Yung-Hung Luo, MD,* Chieh-Hung Wu, MD,* Wen-Shuo
More informationLung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers The Harvard community has made this article openly available. Please share how this access
More informationLung cancer is the leading cause of cancer-related
Original Articles Correlation of Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study
More informationExon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Case Report Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Yu-Ting Wang, Wei-Wei Ning, Jing Li, Jian-n Huang Department of Respiratory Medicine, the First ffiliated
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationFrequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Eur Respir J 2013; 41: 417 424 DOI: 10.1183/09031936.00006912 CopyrightßERS 2013 Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Shang-Gin Wu*,
More informationThe epidermal growth factor receptor (EGFR) gene encodes
ORIGINAL ARTICLE Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity Hye-Suk Han, MD,* Sung-nam Lim,
More informationRESEARCH ARTICLE. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
RESEARCH ARTICLE EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer Satoshi Igawa 1 *, Yuichi Sato 2, Mikiko Ishihara 1, Masashi Kasajima
More informationThoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis
19 th Congress of APSR PG of Lung Cancer (ESAP): Update of Lung Cancer Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis Kazuma Kishi, M.D. Department of Respiratory Medicine,
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationCHAPTER 8A. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well
CHAPTER 8A High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well J.L. Kuiper, E.F. Smit Lung Cancer 2013 Apr;80(1):102-5 Chapter
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationCASE REPORT. Abstract. Introduction. Case Report
SE REPORT n utopsy ase of Two Distinct, cquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung denocarcinoma: Small ell arcinoma Transformation and Epidermal Growth Factor Receptor
More informationLung cancer remains the leading cause of cancer-related
Original Article EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma Kosuke Tanaka, MD,* Toyoaki Hida, MD, PhD,* Yuko Oya, MD,* Tomoyo Oguri, MD,
More informationEGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.48 EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung Tae Won Jang 1, Chul Ho Oak 1, Hee Kyung Chang 2, Soon Jung Suo 3 and Mann Hong Jung
More informationA Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma
Jpn J Clin Oncol 26;36(2)69 75 doi:.93/jjco/hyi228 Original Articles A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma Hiroshi
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationThe ABCs of BAC: Bronchioloalveolar Carcinoma
The ABCs of BAC: Bronchioloalveolar Carcinoma Howard (Jack) West, MD Medical Oncologist Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA March, 2009 President & CEO GRACE
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationRecurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports Puyuan
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationCT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
More informationDirect serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis
ONCOLOGY REPORTS 28: 1815-1821, 2012 Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis CHENGJIN HU 1, XIAOLEI LIU 1, YINGJIAN CHEN 1, XIAOMING
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationRESEARCH. Keywords Non-small cell lung cancer. EGFR gene. T790M mutation. Metastases to central nervous system. EGFR tyrosine kinase inhibitor
Pathol. Oncol. Res. (2014) 20:945 951 DOI 10.1007/s12253-014-9778-6 RESEARCH The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases
More informationLung cancer is ranked as the most common cause of cancer
BRIEF REPORT Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors Susumu Kobayashi, MD, PhD, Hannah M. Canepa, BA, Alexandra S. Bailey, MD, Sohei Nakayama, MD, PhD, Norihiro Yamaguchi,
More informationMolecular Diagnosis of Lung Cancer
Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street
More informationAdenocarcinoma of the lung is the leading cause of cancerrelated
ORIGINAL ARTICLE Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, MD,* Stephen Broderick, MD, Qin Zhou, MA, Dhananjay Chitale, MD, Allan
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLi et al. BMC Genetics (2015) 16:20 DOI /s
Li et al. BMC Genetics (2015) 16:20 DOI 10.1186/s12863-015-0181-4 RESEARCH ARTICLE Open Access Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and
More informationGTS. Earn CME credits at
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center Sandra P. D Angelo, MD, Bernard Park,
More informationBiomedical Research 2017; 28 (14): ISSN X
Biomedical Research 2017; 28 (14): ISSN 0970-938X www.biomedres.info Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Xiaoye Ai, Adalati Yasheng,
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationThe epidermal growth factor receptor (EGFR) is a promising
ORIGINAL ARTICLE Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationSurrogate endpoints for overall survival in advanced non small cell lung cancer patients with mutations of the epidermal growth factor receptor gene
MOLECULAR AND CLINICAL ONCOLOGY 2: 731-736 Surrogate endpoints for overall survival in advanced non small cell lung cancer patients with mutations of the epidermal growth factor receptor gene REIKO YOSHINO
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationYong Zhang 1#, Ling Ye 1#, Huijun Zhang 1, Xuehua Chen 1, Haiying Ji 1, Gang Chen 1, Lu Zhang 2, Tengfei Zhang 2, Meiling Jin 1.
Case Report A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors Yong Zhang 1#, Ling Ye 1#,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationCT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC)
CT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC) Poster No.: C-2192 Congress: ECR 2014 Type: Educational Exhibit Authors: I. Sandu, A. R. Popita, I.-A. Brumboiu; Cluj-Napoca/RO
More informationCT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC)
CT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC) Poster No.: C-2192 Congress: ECR 2014 Type: Educational Exhibit Authors: I. Sandu, A. R. Popita, I.-A. Brumboiu; Cluj-Napoca/RO
More informationDevelopment of a rapid and practical mutation screening assay for human lung adenocarcinoma
1900 Development of a rapid and practical mutation screening assay for human lung adenocarcinoma HELEN CHOI 1,2, JOHANNES KRATZ 1, PATRICK PHAM 1, SHARON LEE 1, ROSHNI RAY 1, YONG-WON KWON 3, JIAN-HUA
More informationCT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses
Mei et al. Cancer Imaging (2018) 18:52 https://doi.org/10.1186/s40644-018-0184-2 REGULAR ARTICLE Open Access CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationShaohua Cui, Liwen Xiong, Yuqing Lou, Huangping Shi, Aiqin Gu, Yizhuo Zhao, Tianqing Chu, Huimin Wang, Wei Zhang, Lili Dong, Liyan Jiang
Original Article Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors Shaohua Cui, Liwen Xiong,
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationPrognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy Fumie Yamashita 1, Koichi Azuma 1 *, Tsukasa Yoshida 1, Kazuhiko Yamada 1,
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationPlasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer
Original Study Plasma Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer David C.L. Lam, Terence C.C. Tam, Kenneth M.K. Lau, Wai-Mui Wong, Christopher K.M. Hui, Jamie C.M.
More informationPrognosis of recurrent non small cell lung cancer following complete resection
1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI
More informationLung cancer affects approximately 1.2 million people annually,
ORIGINAL ARTICLE Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer A Phase II Study Kaoru Kubota, MD, PhD, Yutaka Nishiwaki, MD, Tomohide Tamura,
More informationAnalysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population
Tropical Journal of Pharmaceutical Research August 2016; 15 (8): 1637-1641 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationKey Words: Lung neoplasms; Receptor, epidermal growth factor; Mutation; Sequencing analysis, DNA; Peptide nucleic acids; Pyrosequencing
The Korean Journal of Pathology 2013; 47: 52-60 ORIGINAL ARTICLE Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR
More informationRESEARCH COMMUNICATION
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.3.909 Gefitinib Alone or with Whole Brain Radiotherapy for Patients with Brain Metastasis from NSCLC RESEARCH COMMUNICATION Gefitinib Alone or with Concomitant
More informationCytotoxic chemotherapy such as carboplatin (CBDCA)
ORIGINAL ARTICLE Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Hironori Satoh, MD, PhD,* Akira Inoue,
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationINTRODUCTION. Key words: Gefitinib, EGFR-tyrosine kinase inhibitors, Non Small Cell Lung Cancer
Gefitinib (Iressa) in Non Small Cell Lung Cancer at Kuwait Cancer Control Centre Experience, Kuwait, with Focus on Future Use of EGFR- Tyrosine Kinase Inhibitors Vinay Vyas, Al-Awadi Shafika, Jarslov N,
More informationLung adenocarcinoma: guiding EGFR-targeted therapy and beyond
& 2008 USCAP, Inc All rights reserved 0893-3952/08 $30.00 www.modernpathology.org : guiding EGFR-targeted therapy and beyond Marc Ladanyi and William Pao Departments of Pathology and Medicine, and Human
More informationEpidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
ORIGINAL ARTICLE Korean J Intern Med 218;33:168-175 https://doi.org/1.394/kjim.215.158 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationEpidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research
More informationI appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
More informationCT Findings in the Elderly Lung
CT Findings in the Elderly Lung Poster No.: C-2498 Congress: ECR 2015 Type: Educational Exhibit Authors: P. Ananias, R. Coelho, H. M. R. Marques, O. Fernandes, M. Simões, L. Figueiredo; Lisbon/PT Keywords:
More informationT he utility of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in metastatic nonsmall
OPEN SUBJECT AREAS: NON-SMALL-CELL LUNG CANCER TARGETED THERAPIES Received 30 April 2014 Accepted 15 July 2014 Published 8 August 2014 Correspondence and requests for materials should be addressed to H.L.
More informationSomatic, activating mutations in epidermal growth factor
Brief Report Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort Helena A. Yu, MD,* Maria E. Arcila, MD, Megan Harlan Fleischut, MS, Zsofia Stadler, MD, Marc Ladanyi, MD, Michael
More informationT790M and acquired resistance of EGFR TKI: a literature review of clinical reports
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports Chunyan Ma*, Shuzhen Wei*, Yong Song Review Article Department of Respiratory Medicine, Jinling Hospital, Nanjing University
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationThis online (electronic) survey contains twenty four simple questions. Those marked with an asterisk (*) must be answered.
1. Type of survey This is a retrospective survey that will NOT require the disclosure of any individual patient records or data only information about overall EGFR mutation testing practices and the outcomes
More informationCorrespondence should be addressed to Kumar Prabhash;
Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationFrequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationPurpose. Methods and Materials
Thin-section CT findings in peripheral lung cancer of 3 cm or smaller: are there any characteristic features for predicting tumor histology or do they depend only on tumor size? Poster No.: C-1893 Congress:
More informationPeptide nucleic acid locked nucleic acid polymerase
Peptide nucleic acid locked nucleic acid polymerase Blackwell Publishing Asia chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation Hitoshi
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationEfficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer
Original Article Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer Aiqin Gu, Chunlei Shi, Liwen Xiong, Tianqing Chu, Jun Pei, Baohui Han Department of pulmonary
More information